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httpcense.Abstract Background: Diabetes mellitus is a chronic and debilitating disease. Its complications
give rise to micro and macrovascular diseases which affect eyes, kidneys, heart, blood vessels, nerves
and also lungs. There may be a relationship between diabetes and reduced lung function, so this
study was designed to evaluate the impairment of lung function on spirometry among diabetic
patients.
Objectives: To study the effect of diabetes mellitus on the evolution of respiratory function
parameters.
Patients and methods: Hundred subjects were enrolled in the study, 30 patients with type I,
another 30 patients with type II and 40 subjects were controls. Mean age was 42.78 ± 3.14 years,
45 were males and 55 were females. Mean HbA1C was 8.9 ± 1.1%. 22 patients with diabetes dura-
tion from 5 to 10 years, 38 patients with a duration of more than 10 years. Spirometric tests were
done for all groups by computerized Spirometry with six parameters {Forced vital capacity (FVC),
Forced expiratory volume in ﬁrst second (FEV1), Peak expiratory ﬂow rate (PEFR), Forced expi-
ratory volume in ﬁrst second to forced vital capacity (FEV1/FVC), Peak expiratory ﬂow rate
(FEFR 25–75) and Diffusing capacity for carbon monoxide (DLCO)}.
Result: There was a predominant reduction in all the Spirometric parameters of diabetic patients
toward the restrictive pattern as there was signiﬁcant deterioration in DLCO in comparison with
healthy controls. FVC (p< 0.01), and FEV1/FVC% (p< 0.001) were signiﬁcantly lower in type1
diabetic patients in comparison to those of type II. Impairment of lung functions was obvious with
a longer duration of diabetes.00089246.
(I. Amal Abd El-Azeem).
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514 I. Amal Abd El-Azeem et al.Conclusion: Diabetes is associated with a signiﬁcant impaired pulmonary function in a restrictive
pattern as compared to non diabetics. The pulmonary function impairment was found to be more
marked with diabetic duration especially after 10 years. Subjects with type I diabetes had lower
FVC and FEV1/FVC% than predicted; it could be related to poor glycemic control.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.Introduction
Diabetes Mellitus (DM) is considered as a metabolic disorder
of multiple aetiologies (genetic and environmental). It is char-
acterized by chronic hyperglycemia due to absolute or relative
insulin deﬁciency (defects in either insulin secretion or insulin
action or both). This results in disturbances of carbohydrate,
protein and fat metabolism [1]. The major side effects of diabe-
tes mellitus are due to its microangiopathic and macroangio-
pathic complications, which affect eyes, kidneys, nerves,
heart, major vessels and the lungs [2].
Type1 or IDDM is due to insulin deﬁciency caused by auto-
immune destruction of B cells in the islets of pancreas. The sec-
ond form of diabetes mellitus is Type 2 or NIDDM, is
characterized by insulin resistance and impaired insulin recep-
tors. It is a common type of diabetes and usually develops after
the age of 40 years. It is associated with normal B cell mor-
phology [3].
The lung was targeted in diabetic microangiopathy, histo-
pathology showed basal lamina thickening and ﬁbrosis [4].
The lung is rich in micro-vascular circulation and abundant
connective tissue that raises the possibility of lung affection
by microangiopathic process and non-enzymatic glycosylation
of tissue proteins, induced by chronic hyperglycemia, render-
ing the lung a ‘‘target organ’’ in diabetic patients [5]. The nor-
mal lung mechanics and gas exchange are inﬂuenced by the
integrity of pulmonary connective tissue and microvascula-
tures, so any abnormalities in either of the two structural com-
ponents lead to abnormal pulmonary function tests (PFT) [6].
The association between diabetes and impaired lung func-
tion was noticed and necessitated attention. Diabetes mellitus
is associated with increased levels of systemic inﬂammatory
mediators and inﬂammatory markers which together with
microangiopathy are accused in alterations of lung matrix pro-
teins and hence the impairment of pulmonary functions [7].
It is likely that persistent inadequate blood glucose control
over time may alter the regulation of inﬂammatory pathways
that are involved in pulmonary function impairment; this
impairment is mainly restrictive with obvious reduction in dif-
fusing capacity to carbon monoxide [8].Aim of the work
We aimed in this study to assess the status of pulmonary func-
tion in diabetics.
Subjects and methods
A total number of 100 subjects were referred from outpatient
clinics of the internal medicine department of the Sabah hospi-
tals, from January 2012 to November 2012. 30 patients hadtype 1 DM and 30 patients had type 2 DM. 40 normal individ-
uals were included as the control group who had no history of
DM as conﬁrmed by normal fasting, postprandial blood sugar
and urine for sugar. These persons had identical characters for
those of DM regarding age, sex and body mass index with sim-
ilar exclusion criteria as the study group. Consent was taken
from all the subjects.
Inclusion criteria
Previously diagnosed diabetic patients which are uncontrolled
or poorly controlled for more than 5 years duration of the
illness.
Exclusion criteria
Patients with a history of smoking, acute or chronic respira-
tory disease, history of occupational exposure, neuromuscular
or cardiovascular diseases or any physical disability that may
affect lung function as kyphoscoliosis, pectus excavatum and
pectus carinatum. Obese persons were excluded (BMI more
than 30 kg/m2).Method
1. Detailed history and physical examination were carried out
for all groups regarding the respiratory, cardiac and neuro-
muscular systems to be sure that these systems are clinically
free.
2. X-ray chest, ECG and ECHO were done to all groups to
exclude any hidden pulmonary or cardiac problems.
3. Pulmonary function tests were performed by using a
computerized system (Jaeger) model. Pulmonary function
parameters which include forced expiratory volume in one sec-
ond (FEV1), forced vital capacity (FVC), and the ratio of the
forced expiratory volume in 1 s to the forced vital capacity in
percentage (FEV1/FVC%) Peak expiratory ﬂow rate (PEFR),
forced expiratory ﬂow in 25–75% of vital capacity (FEF25–75)
and DLCO was measured by the single-breath method using
gas chromatographic equipment.
4. Biochemical investigations: Blood samples were obtained
after a 12 h overnight fast for the estimation of levels of blood
glucose and repeated two hours postprandially. The oral glu-
cose tolerance test (OGTT) was done for the control group
only to exclude diabetes in addition to impaired fasting glyce-
mia (IFG) and impaired glucose tolerance (IGT). Fasting
blood glucose of P126 mg/dL) was used to deﬁne diabetes
while the fasting blood glucose of P110 mg/dL and
<126 mg/dL was used to deﬁne IFG. IGT was deﬁned as a
2 h blood glucose post 75 g of glucose of P140 mg/dL and
<200 mg/dL [9]. Only control subjects with a normal fasting
blood glucose of <110 mg/dL and 2 h post oral glucose of
<140 mg/dL were recruited into the study. HbA1c was used
Table 1 Subjects with diabetes mellitus: characteristic at the
start.
Number 100
Age (years) 42.78 ± 3.14
Sex 55 F & 45 M
Types of subjects 30 type I DM & 30 type II DM & 40 as controls
DM duration (years) 5–10 years: 22 patients
>10 years: 38 patients
Hb A1c 8.9 ± 1.1
Table 3 PFT parameters between diabetic patients according
to the duration of diabetes.
PFT parameters 5–10 years >10 years P value
Mean ± SD Mean ± SD
FEV1 (L) 1.90 ± 0.7 1.80 ± 0.91 0.64NS
FVC (L) 2.3 ± 0.9 2.1 ± 0.7 0.35NS
FEV1/FVC% 82.6 ± 0.14 85.19 ± 0.48 0.15NS
PEFR (l/S) 3.51 ± 0.3 3.29 ± 0.71 0.53NS
FEF 25–75% (l/S) 1.59 ± 0.71 1.48 ± 0.49 0.45NS
DLCO (ml/min/mmHg) 14.10 ± 2.7 13.32 ± 2.1 0.84NS
Table 4 PFT parameters according to the type of diabetes.
PFT parameters Type I DM Type II DM P value
Mean ± SD Mean ± SD
FEV1(L) 1.5 ± 0.5 1.70 ± 0.1 0.52NS
FVC (L) 1.6 ± 0.3 2.0 ± 0.2 0.05S
FEV1/FVC% 93.8 ± 0.2 85.1 ± 0.1 0.05S
PEFR (l/S) 3.12 ± 0.2 3.25 ± 0.6 0.12NS
FEF 25–75% (l/S) 1.21 ± 0.3 1.40 ± 0.5 0.31NS
Pulmonary function changes in diabetic lung 515as an index of diabetic control over the last 3 months .Values
over 7.5% were considered as poor glycemic control and lower
than this level was considered as good glycemic control. [10].
5. Anthropometric measurements: Height and weight of all
subjects were recorded and BMI was calculated by the formula
of weight/height2.
The pulmonary function parameters were compared be-
tween the diabetics and control groups then between the dia-
betics according to the type and duration of diabetes.DLCO (ml/min/mmHg) 13.11 ± 1.2 13.97 ± 1.9 0.24NSResult
Hundred patients were included in this study with a mean age
of 42.78 ± 3.14. Of these 55 were females and 45 were males.
30 patients had type I diabetes mellitus (DM) and 30 patients
had type II DM while 40 subjects were controls. Regarding the
duration of diabetes, 22 patients had DM from 5 to 10 years
while 38 patients had DM for more than 10 years. For the dia-
betic subjects, the mean HbA1c was 8.9 ± 1.1 indicating poor
glycemic control (Table 1). The main ﬁnding is that the venti-
latory functions were signiﬁcantly reduced in diabetic subjects
compared with controls. The ventilatory dysfunction was pre-
dominantly restrictive as shown by the preserved ratio of
FEV1/FVC% and the reduced DLCO as compared with the
controls (Table 2).
Our study showed no signiﬁcant difference in pulmonary
function parameters between diabetic groups regarding the
duration of diabetes but reduction in the ventilatory function
was observed as the duration of diabetes increased (Table 3).
Regarding the type of diabetes, there was a signiﬁcant
reduction in FVC and FEV1/FVC in type I DM while other
ventilatory function parameters revealed no signiﬁcance but
more reduction in the ventilatory function was observed be-
tween type I and type II DM (Table 4).Table 2 PFT parameters in comparison between diabetes and cont
PFT parameters Diabetes mellitus (n= 60)
Mean ± SD
FEV1 (L) 1.7 ± 0.47
FVC (L) 2.02 ± 0.41
FEV1/FVC% 84.15 ± 0.53
PEFR (l/S) 3.34 ± 1.05
FEF 25–75% (l/S) 1.28 ± 0.6
DLCO (ml/min/mmHg) 13.71 ± 2.5Statistical analysis
The results were analyzed using mean and standard deviation
for all variables and comparison was done using the Student’s
t-test. Frequencies were generated for categorical variables
and compared with the chi square test. p< 0.05 was accepted
as signiﬁcant.
Discussion
Diabetic patients are susceptible to a series of complications
including microvascular complications like diabetic retinopa-
thy, diabetic nephropathy and diabetic neuropathy. The lungs
are affected by diabetic microangiopathy [11]. The effect of
diabetes on the ventilatory function is the focus of this study.
The main ﬁnding is that the ventilatory function is signiﬁcantly
reduced in diabetic patients compared with the controls. Ven-
tilatory dysfunction in diabetics was predominantly restrictive
as shown by the preserved ratio of FEV1/FVC% and de-
creased carbon monoxide diffusing capacity (DLCO) com-
pared with controls. The histopathological ﬁnding seen in
the diabetic lung revealed microangiopathic changes such as
ﬁbrosis and basal lamina thickening that will lead to arol groups.
Controls (n= 40) P value
Mean ± SD
2.89 ± 0.35 0.01S
3.11 ± 0.52 0.01S
92.91 ± 0.61 0.001S
5.89 ± 0.8 0.001S
2.61 ± 0.34 0.001S
22.51 ± 2.7 0.001S
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tion in Saudi Arabia also had similar ﬁndings [13]. Several pre-
vious studies have found a signiﬁcant correlation between
uncontrolled DM and pulmonary function impairment which
support the concept that, the lung is a target organ for diabetic
microangiopathy [8]. Our ﬁndings were consistent with those
met by Irfan et al. [14] and Ljubic et al. [15] as they observed
a signiﬁcant reduction in DLCO in patients with diabetic
microangiopathy. The possible pathophysiological mecha-
nisms are that, the lung has an extensive capillary bed, so it
is expected to be affected by diabetic microangiopathy [16].
Also, postmortem examination revealed thickened alveolar
epithelial and pulmonary capillary basal laminae in diabetic
patients which explained the deteriorated pulmonary gas ex-
change and a decrease in DLCO [17].
Many post-mortem studies on diabetic patients explained
the relationship between microangiopathy and the impairment
of DLCO as they show that the thickening of alveolar epithe-
lial and pulmonary capillary basal laminae is considered to be
the initial lesion in the development of diabetic microangiopa-
thy [18]. Keerthi et al. postulated that the observed decrease in
TLC might be due to an altered collagen matrix in the lung. A
signiﬁcant decrease in lung volumes was found and this was
thought to be due to decreased lung compliance due to restric-
tion of chest wall expansion as a result of altered collagen
metabolism or altered collagen/elastin ratio [1].
Many explanations were given to explain the restrictive ven-
tilatory dysfunction in diabetic patients but these explanations
were not investigated in our study. These explanations include
the involvement of the neuromuscular respiratory muscles due
to diabetic neuropathy of the thoracic nerves that contributes
to the respiratory dysfunction [19]. Other investigators found
that hyperglycemia was associated with poor skeletal muscle
strength due to increased protein catabolism, for this reason
respiratorymuscle endurance also decreased in diabetesmellitus
[20]. Ozmen et al. [21] investigated lung function in diabetics and
age-matched control subjects and they found that, the lung elas-
tic recoil was decreased in these patients and because the elastic
structure of the lung supports the intrathoracic airways and
helps to maintain their patency, the patients with diabetes were
at risk for developing chronic airﬂow obstruction. Others found
both decreased lung elasticity and CO transfer capacity and also
decreased pulmonary capillary blood volume [3]. Meo et al. [22]
andDavis et al. [23] found that therewas a combined obstructive
and restrictive pattern of pulmonary function in diabetics but it
was predominately restrictive.
Regarding the duration of diabetes, the current study
showed a reduction in the pulmonary function parameters with
increasing duration of the disease but there was no signiﬁ-
cance. Davis et al. [24] supported this concept as he found that
there was a clear decline in PFT with an increase in the dura-
tion of DM, but there was no signiﬁcance. The same ﬁndings
were consistent with the results met by Sinhs et al. [25] as they
found a reduced ventilatory function in diabetics and they re-
lated this observation to the inﬂammatory process associated
with diabetes and as this disease is progressive, progressive de-
crease in lung function may be mediated via progression of
inﬂammation, the severity of which would increase with a
longer duration of diabetes. Shravya et al. [26] showed that
DLCO% decreased signiﬁcantly as the duration of DM in-
creased and the reduction was greater in patients with diabetic
microangiopathy and in type I DM. Also Van den Borst et al.[27] showed a negative correlation between DLCO% and the
duration of the disease. Hsia and Raskin [28] concluded that
60% of the diabetic population had abnormal pulmonary
function, mild reduction of lung elastic recoil and/or a reduc-
tion in pulmonary capillary blood volume. The degree of pul-
monary dysfunction was correlated with the duration of DM,
which was consistent with our study. Regarding the type of
diabetes, we observed a reduction in pulmonary function
parameters including a decrease in DLCO in both types of dia-
betes, but the reduction was more in type I than type II. Sev-
eral pathological conditions may affect the lungs of type-1
diabetic patients, as chronic hyperglycemia causes microvascu-
lar changes as the thickening of basal laminae in the smaller
vessels of the lungs and this causes a reduction of vascular dif-
fusing capacity [24]. It was also observed that hyperglycemia
affects the lung by nonenzymatic glycosylation of the chest
wall and bronchial tree proteins which prevent lung expansion
so, the volume and elastic recoil of the lung were reduced in
type-1 diabetic patients [28]. Our observations are in agree-
ment with Khan et al. [20] who reported that both IDDM
and NIDDM were associated with a slight reduction in
FVC. This reduction was more pronounced in diabetic subjects
treated with insulin (type I). Similar observations were met by
Sreeja et al. [29]. Fimognari et al. [30] and Nakagima et al. [31]
who reported reduced FVC and normal FEV1/FVC and con-
cluded that restrictive pulmonary function but not the obstruc-
tive pattern might be associated with metabolic disorders and
the metabolic syndrome. The possible explanation of restric-
tive ventilatory dysfunction is non-enzymatic glycosylation of
pulmonary collagen leading to the accumulation of advanced
glycosylation end products and resulting in increased cross-
link formation [31]. Another explanation was given by Pinar
et al. [18]. who said that the long duration of DM and the pres-
ence of high grade pulmonary microangiopathy and the de-
crease in DLCO with diabetes mellitus type 1 were thought
to be due to the fact that the patients using insulin usually
had a longer duration of disease. Similar observations were
met by Sina et al. [32], Sanjeev et al. [33], Falah [3], Benbassat
et al. [34], Khan et al. [20] and Nandhini et al. [35].
Conclusion
 The present study showed signiﬁcant restrictive ventilatory
dysfunction in uncontrolled diabetic patients with microan-
giopathy as compared to control subjects.
 The PFT parameters were affected more with longer dura-
tion of DM.
 DM type I affects lung function more than DM type II.
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